Caribou Has $94.8 Million in Liquidity as It Halts Development of Two Programs and Explores Strategic Options
Key Facts
Caribou Biosciences reported a U.S. GAAP net loss of $26.6 million, or $0.25 per share, for the third quarter ended September 30, 2026. The company compared that with a loss of $27.5 million, or $0.30 per share, in the year-earlier quarter. Revenue from licenses and agreements with third parties was $1.6 million, compared with $2.2 million a year earlier. The results showed a decline in quarterly revenue alongside a year-over-year decrease in net loss. The figures come as the company restructures its operations and considers strategic alternatives after deciding to halt development of two cell therapy programs.
Cash, cash equivalents and marketable securities totaled $94.8 million at September 30, 2026, compared with $142.8 million at December 31, 2025. That balance puts available liquidity at the center of an assessment of the company's path as it restructures and reviews strategic options. Caribou said in its quarterly report that its existing cash and marketable securities would fund operations for at least the 12 months following the report's filing date. The company tied that estimate to its current assumptions about its operations. It also reported net cash used in operating activities of $72.3 million in the first nine months of 2026, compared with $90.2 million in the same period of 2025.
Research and development expenses fell to $21.3 million in the third quarter of 2026, from $22.4 million in the year-earlier period. General and administrative expenses declined to $7.9 million, compared with $9.2 million a year earlier. For the first nine months of 2026, the company said lower research and development and general and administrative expenses contributed to the decrease in cash used in operations. It added that changes in operating assets and liabilities included factors that offset that decrease. These items reflect year-over-year declines in the two expense categories highlighted by the company in its quarterly results.
Caribou announced on October 6, 2026, that its board had approved a restructuring of operations as the company explores strategic alternatives to maximize shareholder value. The plan includes halting clinical trials and further development activities for the vispa-cel and CB-011 programs. It also includes a significant workforce reduction and other cost-cutting measures. The company attributed the decision to the current financing environment for chimeric antigen receptor T-cell therapies, which it said had made it more difficult to secure the capital needed to continue developing the two programs. The company said the restructuring is part of its review of strategic options.
The alternatives cited by the company include a merger, acquisition, business combination or other strategic transactions involving the company or its assets. It also cited a possible dissolution and liquidation of the company among the options it may consider. The board appointed Wedbush Securities as Caribou's exclusive financial adviser to help evaluate the alternatives. The company has made no commitment that the review will result in a transaction. The announced range of options remains broad, from transactions involving the company or its assets to dissolution and liquidation.
Caribou estimated one-time restructuring costs of about $10.0 million to $11.0 million, mainly comprising severance, continued health coverage and related costs. It also estimated future costs of between $5.0 million and $8.0 million to wind down the Phase 1 ANTLER trial of vispa-cel and the Phase 1 CaMMouflage trial of CB-011. In June 2026, data from a group of 27 patients in the ANTLER study showed an overall response rate of 82% and a complete response rate of 67%. Median progression-free survival in that group was 17.1 months, and the company said the group best represented the treatment regimen and target population for the planned pivotal trial. In data from the CaMMouflage study presented in the same month, 12 patients who had not previously received BCMA-directed treatment had an overall response rate of 92%, with at least half still in complete response or better after 15 months.
Caribou had projected in August 2026 that it would report preliminary safety and efficacy data in the second half of the year from an expansion of the CB-011 study to more than 15 patients, alongside longer follow-up for the recommended-dose cohort of 12 patients. But in October it announced that it was halting the trial and further development of the program. The company has not set a date for completing its review of strategic alternatives. It said it does not plan to provide further updates until the board approves a course of action, the review concludes, or disclosure becomes appropriate or required. Caribou shares, listed under the ticker CRBU, closed at $0.4123 in the November 5, 2026, session.